Colchicine Micronized

Indena SpA offers a wide range of pharmaceutical products which includes silymarin. Botanical origin: silybum marianum (l.) gaertn. fruit. Biological activity: hepatoprotector. Contact us for more information.

Indena SpA offers a wide range of pharmaceutical products which includes st. john's wort extract. Botanical origin: hypericum perforatum l. flowering top. Biological activity: anti-depressive. Contact us for more information.

Indena SpA offers a wide range of pharmaceutical products which includes thiocolchicoside. Botanical origin: gloriosa superba l. seed. Biological activity: muscle relaxant. Contact us for more information.

Indena SpA offers a wide range of pharmaceutical products which includes cascara sagrada extract. Botanical origin: rhamnus purshiana dc. bark. Biological activity: laxative. Contact us for more information.

Indena SpA offers a wide range of pharmaceutical products which includes centella asiatica selected triterpenes. Botanical origin: centella asiatica (l.) urban leaf. Biological activity: cicatrizing-trophodermic. Contact us for more information.

Indena SpA offers a wide range of pharmaceutical products which includes chamomile extract. Botanical origin: matricaria recutita l. flowering head, leave. Biological activity: spasmolytic. Contact us for more information.

PURE MOLECULE ISOLATED OR DERIVED FROM PLANTS

Proprietary crystalline form; semisynthetic taxane derivative. Botanical origin: taxus baccata L. twig and leaf. Biological activity: anti-mitotic, anticancer. 

Antimitotic / Anticancer

Natural, from Cannabis sativa L.

Antigout

Chemical intermediate

Natural products can be characterized by complex structure, limited availability, and exceptional potency, whose combination makes it challenging their development as API. Success requires integration of expertise in different areas, including the construction of a sustainable supply chain for the starting biomass, the capacity to manipulate high-potency products in a GMP environment, and the versatility to strategically complement isolation with semi-synthesis, total synthesis and biotechnology. In this context, mutual thrust between the service provider company and the drug candidate owner is critical, and the successful development of the anticancer drug tigilanol tiglate will give the opportunity to address these issues.

We have a unique expertise in developing and manufacturing HPAPIs. The company is equipped with kilolabs (for clinical and small commercial batches) and large industrial suite for HPAPIs with an OEL>20 ng/m3.